BALOXAVIR Drug Patent Profile
✉ Email this page to a colleague
When do Baloxavir patents expire, and what generic alternatives are available?
Baloxavir is a drug marketed by Norwich and is included in one NDA.
The generic ingredient in BALOXAVIR is baloxavir marboxil. Two suppliers are listed for this compound. Additional details are available on the baloxavir marboxil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Baloxavir
A generic version of BALOXAVIR was approved as baloxavir marboxil by NORWICH on June 17th, 2026.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BALOXAVIR?
- What are the global sales for BALOXAVIR?
- What is Average Wholesale Price for BALOXAVIR?
Summary for BALOXAVIR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | BALOXAVIR at DailyMed |
US Patents and Regulatory Information for BALOXAVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norwich | BALOXAVIR MARBOXIL | baloxavir marboxil | TABLET;ORAL | 217449-001 | Jun 17, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Norwich | BALOXAVIR MARBOXIL | baloxavir marboxil | TABLET;ORAL | 217449-002 | Jun 17, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
